Company status

No longer trading

No closing price was ever reported for it. It has left the AI-ranked universe. The score and rank below are its final ones, from September 26, 2026.

SVA

SINOVAC BIOTECH LTD SVA

NasdaqunknownHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

Final 13F Pro quality score

Final rank #2,738 of 2,969 · as of September 26, 2026

Why it scores 23Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$386.01M

Quarter to Dec 31

Net income

$-198.84M

Quarter to Dec 31

Free cash flow

$-561.10M

Quarter to Dec 31

Operating margin

-127.0%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$224.91M total
ORBIMED ADVISORS LLC
$184.47M0.0%
Vivo Capital, LLC
$38.19M0.0%
Neumann Advisory Hong Kong Ltd
$2.04M0.0%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$106.3K0.0%
MORGAN STANLEY
$59.2K0.0%
WELLS FARGO & COMPANY/MN
$29.6K-4.8%
UBS Group AG
$16.0K+11.2%
HARBOUR INVESTMENTS, INC.
$503-6.0%
Horizon Investments, LLC
$336-50.0%
ROYAL BANK OF CANADA
$00.0%
RENAISSANCE TECHNOLOGIES LLC
$00.0%
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
$00.0%
GEODE CAPITAL MANAGEMENT, LLC
$00.0%
ASSETMARK, INC
$0+142.3%
Financial Gravity Companies, Inc. (FGCO)
$0--
Transamerica Financial Advisors, LLC
$00.0%
Tower Research Capital LLC (TRC)
$00.0%
Skandinaviska Enskilda Banken AB (publ)
$0-50.0%
Spark Investment Management LLC
$00.0%
FINANCIAL CONSULATE, INC
$00.0%
IFP Advisors, Inc
$00.0%
OSAIC HOLDINGS, INC.
$0-54.5%
Integrated Wealth Concepts LLC
$0New
Buck Wealth Strategies, LLC
$0New
Atlantic Edge Private Wealth Management, LLC
$00.0%
See all 29 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Operating Margin

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Debt/Equity

FY 2025
EDGAR

Loading ratio trend…

SVA key financials by period

Reported revenue, net income and operating margin by fiscal year, from SINOVAC BIOTECH LTD's annual filings on SEC EDGAR.

SINOVAC BIOTECH LTD reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$386.0M$-198.8M-127.0%
FY 2024$361.4M$40.7M-139.9%
FY 2023$470.2M$-13.5M-151.9%
FY 2022$1.5B$14.5M-34.5%
FY 2021$19.4B$8.1B91.0%
FY 2020$510.6M$110.4M42.2%
Source: SVA filings on SEC EDGAR →

About SINOVAC BIOTECH LTD (SVA): stock profile, AI score and financials

No longer trading: SINOVAC BIOTECH LTD (SVA) no longer trades and has left 13F Pro's AI-ranked universe. No closing price was ever reported for it. It has left the AI-ranked universe. The score and rank below are its final ones, from September 26, 2026. SINOVAC BIOTECH LTD (SVA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks SVA using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (FY 2025), SINOVAC BIOTECH LTD reports quarterly revenue of $386.0M, net income of $-198.8M, an operating margin of -127.0%. Top institutional holders of SVA by reported 13-F value include ORBIMED ADVISORS, Vivo Capital, Neumann Advisory Hong Kong Ltd, based on the most recent SEC filings. SVA trades on the Nasdaq exchange and files with the SEC under CIK 1084201. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SINOVAC BIOTECH LTD directly from SEC EDGAR.

SEC EDGAR: CIK 1084201 →